SCHEMBL5115958

SCHEMBL5115958

NC(=O)C(c1ccccc1)N(Cc1cccc(C(=O)O)c1)S(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
TAS2R14 Q9NYV8 6/20 0.50
CXCR3 P49682 1/20 0.50
PSEN1 P49768 1/20 0.49
PSEN2 P49810 1/20 0.49
APH1B Q8WW43 1/20 0.49
NCSTN Q92542 1/20 0.49
APH1A Q96BI3 1/20 0.49
PSENEN Q9NZ42 1/20 0.49
POLB P06746 1/20 0.46
MEP1B Q16820 4/20 0.45
GAA P10253 1/20 0.45
TRPM8 Q7Z2W7 1/20 0.44
MEP1A Q16819 1/20 0.44
DAGLA Q9Y4D2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5115947 1.00 MEN1 (0.51) MEN1KMT2ATAS2R14CXCR3PSEN1
SCHEMBL5127304 0.90 TAS2R14 (0.53) MEN1KMT2ATAS2R14CXCR3PSEN1
SCHEMBL5127299 0.90 TAS2R14 (0.53) MEN1KMT2ATAS2R14CXCR3PSEN1
SCHEMBL5121099 0.89 MAPT (0.48) MEN1KMT2ATAS2R14CXCR3PSEN1
SCHEMBL5121105 0.89 MAPT (0.48) MEN1KMT2ATAS2R14CXCR3PSEN1
SCHEMBL5117393 0.89 TAS2R14 (0.52) MEN1KMT2ATAS2R14CXCR3PSEN1
SCHEMBL5117399 0.89 TAS2R14 (0.52) MEN1KMT2ATAS2R14CXCR3PSEN1
SCHEMBL5119882 0.88 TAS2R14 (0.50) MEN1KMT2ATAS2R14CXCR3PSEN1
SCHEMBL5116418 0.88 TAS2R14 (0.50) MEN1KMT2ATAS2R14CXCR3PSEN1
SCHEMBL5119873 0.88 TAS2R14 (0.50) MEN1KMT2ATAS2R14CXCR3PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7345095-B2 Sulfonamide compounds for the treatment of neurodegenerative disorders PFIZER INC (US) 2008-03-18 US disclosed
US-20070129349-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER INC 2007-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129349-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PSEN1, APP, PSEN2 MEN1 766/4885KMT2A 1535/4885TAS2R14 1345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.